PMID- 31513823
OWN - NLM
STAT- MEDLINE
DCOM- 20200203
LR  - 20200203
IS  - 1872-8227 (Electronic)
IS  - 0168-8227 (Linking)
VI  - 156
DP  - 2019 Oct
TI  - The effects of DPP4 inhibitors on the levels of plasma catecholamines and their 
      metabolites in patients with type 2 diabetes.
PG  - 107832
LID - S0168-8227(19)30880-0 [pii]
LID - 10.1016/j.diabres.2019.107832 [doi]
AB  - AIMS: Dipeptidyl peptidase 4 inhibitors (DPP4Is) can increase sympathetic 
      activity. We aimed to evaluate the direct association between serum DPP4 activity 
      and sympathetic activity in humans. METHODS: Fasting serum DPP4 activity and 
      plasma levels of catecholamines and their metabolites were measured in 211 
      patients with type 2 diabetes mellitus (T2DM) treated with DPP4I (n = 146) or 
      non-DPP4I therapy (n = 65) and in healthy control subjects (n = 30). RESULTS: 
      Although there were no differences in plasma levels of catecholamines and their 
      metabolites between the DPP4I and non-DPP4I groups, the levels in both of these 
      groups were lower than those in the healthy control group. In DPP4I-treated 
      patients, serum DPP4 activity showed an inverse correlation with plasma levels of 
      norepinephrine (NE) (r = -0.339, p < 0.01), metanephrine (MET) (r = -0.251, 
      p < 0.01) and normetanephrine (r = -0.312, p < 0.001). In addition, plasma MET 
      level showed a weak inverse correlation with serum DPP4 activity in the combined 
      T2DM group. In DPP4I-treated patients, the inverse correlation between DPP4 
      activity and plasma NE remained significant even after multiple adjustments. 
      CONCLUSIONS: Our results suggest that although sympathetic activity is lower in 
      patients with T2DM, the greater the suppression of DPP4 activity by DPP4I 
      therapy, the greater the increase in sympathetic activity is, which may have 
      clinical implications in high risk T2DM patients.
CI  - Copyright (c) 2019 Elsevier B.V. All rights reserved.
FAU - Kim, Tae Hun
AU  - Kim TH
AD  - Gachon University, School of Medicine, Incheon, Republic of Korea.
FAU - Lee, Kiyoung
AU  - Lee K
AD  - Department of Internal Medicine, Gil Medical Center, Gachon University College of 
      Medicine, Incheon, Republic of Korea.
FAU - Park, Ie Byung
AU  - Park IB
AD  - Department of Internal Medicine, Gil Medical Center, Gachon University College of 
      Medicine, Incheon, Republic of Korea.
FAU - Choi, Cheol Soo
AU  - Choi CS
AD  - Department of Internal Medicine, Gil Medical Center, Gachon University College of 
      Medicine, Incheon, Republic of Korea.
FAU - Ahn, Tae Hoon
AU  - Ahn TH
AD  - Department of Internal Medicine, Gil Medical Center, Gachon University College of 
      Medicine, Incheon, Republic of Korea. Electronic address: encore@gilhospital.com.
FAU - Lee, Dae Ho
AU  - Lee DH
AD  - Department of Internal Medicine, Gil Medical Center, Gachon University College of 
      Medicine, Incheon, Republic of Korea. Electronic address: drhormone@naver.com.
LA  - eng
PT  - Journal Article
DEP - 20190909
PL  - Ireland
TA  - Diabetes Res Clin Pract
JT  - Diabetes research and clinical practice
JID - 8508335
RN  - 0 (Catecholamines)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Catecholamines/*metabolism
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Dipeptidyl-Peptidase IV Inhibitors/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - Catecholamines
OT  - Dipeptidyl peptidase 4
OT  - Dipeptidyl peptidase 4 inhibitors
OT  - Sympathetic nervous system
OT  - Type 2 diabetes mellitus
EDAT- 2019/09/13 06:00
MHDA- 2020/02/06 06:00
CRDT- 2019/09/13 06:00
PHST- 2019/06/24 00:00 [received]
PHST- 2019/08/11 00:00 [revised]
PHST- 2019/08/29 00:00 [accepted]
PHST- 2019/09/13 06:00 [pubmed]
PHST- 2020/02/06 06:00 [medline]
PHST- 2019/09/13 06:00 [entrez]
AID - S0168-8227(19)30880-0 [pii]
AID - 10.1016/j.diabres.2019.107832 [doi]
PST - ppublish
SO  - Diabetes Res Clin Pract. 2019 Oct;156:107832. doi: 10.1016/j.diabres.2019.107832. 
      Epub 2019 Sep 9.